Real world study: A look at BMS' China Sprycel registry
This article was originally published in Scrip
When staff at Bristol-Myers Squibb China did a search on clinicaltrials.gov for observational studies for adult chronic myeloma leukemia (CML) conducted in China, what they found was puzzling – there were zero results.
You may also be interested in...
From enforced detention to hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.